131 related articles for article (PubMed ID: 15552189)
1. Drug pullout. Massive recall of Vioxx poses logistical problems.
Becker C
Mod Healthc; 2004 Oct; 34(42):17. PubMed ID: 15552189
[No Abstract] [Full Text] [Related]
2. The fallout from Vioxx.
DeMaria AN
J Am Coll Cardiol; 2004 Nov; 44(10):2080-1. PubMed ID: 15542295
[No Abstract] [Full Text] [Related]
3. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
Couzin J
Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258
[No Abstract] [Full Text] [Related]
4. COX-2 inhibitor use after Vioxx: careful balance or end of the rope?
Fendrick AM
Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263
[No Abstract] [Full Text] [Related]
5. The lessons of Vioxx.
Frazier KC
N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497
[No Abstract] [Full Text] [Related]
6. Was Vioxx really that dangerous?
Park A
Time; 2005 Feb; 165(9):52. PubMed ID: 15765852
[No Abstract] [Full Text] [Related]
7. Under surveillance.
Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
[No Abstract] [Full Text] [Related]
8. The Vioxx debacle revisited.
Mohapatra PR; Janmeja AK
Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
[No Abstract] [Full Text] [Related]
9. The Vioxx debacle revisited.
Daikh DI
Am J Med; 2005 Sep; 118(9):1057. PubMed ID: 16164908
[No Abstract] [Full Text] [Related]
10. The Vioxx debacle revisited.
Good CB; Kelley CL
Am J Med; 2005 Sep; 118(9):1055-6; author reply 1056-7. PubMed ID: 16164902
[No Abstract] [Full Text] [Related]
11. Rofecoxib, Merck, and the FDA.
Villalba L; Witter J
N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
[No Abstract] [Full Text] [Related]
12. How to avoid another 'Vioxx'.
Frantz S
Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
[No Abstract] [Full Text] [Related]
13. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
Meyer CH
Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404
[No Abstract] [Full Text] [Related]
14. Learning the value of drugs--is rofecoxib a regulatory success story?
Eisenberg RS
N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
[No Abstract] [Full Text] [Related]
15. Merck withdraws Vioxx; FDA issues public health advisory.
FDA Consum; 2004; 38(6):11. PubMed ID: 15675020
[No Abstract] [Full Text] [Related]
16. Balancing risks and benefits in pain medicine: wither Vioxx.
Gallagher RM
Pain Med; 2004 Dec; 5(4):329-30. PubMed ID: 15563316
[No Abstract] [Full Text] [Related]
17. Will Merck survive Vioxx?
Simons J; Stipp D
Fortune; 2004 Nov; 150(9):90-2, 94, 96-7 passim. PubMed ID: 15543824
[No Abstract] [Full Text] [Related]
18. FDA warns Merck over its promotion of rofecoxib.
Josefson D
BMJ; 2001 Oct; 323(7316):767. PubMed ID: 11588068
[No Abstract] [Full Text] [Related]
19. What are the real lessons from Vioxx?
Edwards IR
Drug Saf; 2005; 28(8):651-8. PubMed ID: 16048352
[No Abstract] [Full Text] [Related]
20. Cyclooxygenase-2 inhibitors and cardiovascular risk.
Smith ER
Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
[No Abstract] [Full Text] [Related]
[Next] [New Search]
